↓ Skip to main content

Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women

Overview of attention for article published in Journal of Ovarian Research, May 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#36 of 383)
  • Good Attention Score compared to outputs of the same age (75th percentile)

Mentioned by

twitter
6 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women
Published in
Journal of Ovarian Research, May 2018
DOI 10.1186/s13048-018-0411-2
Pubmed ID
Authors

Mario Montanino Oliva, Giovanna Buonomo, Marco Calcagno, Vittorio Unfer

Abstract

Myo-inositol (MI), successfully used in polycystic ovary syndrome (PCOS), was administered with α-LA to exploit its action of favouring the passage of other molecules through biological barriers, and also considering its anti-inflammatory effect. PCOS patients, according to the Rotterdam ESHRE-ASRM criteria, with anovulation and infertility > 1 year, were included in this open and prospective study. The preliminary phase was aimed at determining a set of MI-resistant PCOS patients. This treatment involved 2 g MI, taken twice per day by oral route, for three months. The Homeostasis Model Assessment (HOMA) index and MI plasma levels were measured. In the main phase, previously selected MI-resistant patients received the same daily amount of MI plus 50 mg α-LA twice a day, for a further three months. Ovulation was assessed using ultrasound examination on days 12, 14 and 20 of the cycle. The HOMA index, lipid, hormone and MI plasma levels were detected at baseline and at the end of this phase. Thirty-seven anovulatory PCOS subjects were included in the study. Following MI treatment, 23 of the 37 women (62%) ovulated, while 14 (38%) were resistant and did not ovulate. In the latter group, MI plasma levels did not increase. These MI-resistant patients underwent treatment in the main phase of the study, receiving MI and α-LA. After this combined treatment, 12 (86%) of them ovulated. Their MI plasma levels were found to be significantly higher than at baseline; also, a hormone and lipid profile improvement was recorded. The combination of MI with α-LA allowed us to obtain significant progress in the treatment of PCOS MI-resistant patients. Therefore, this new formulation was able to re-establish ovulation, greatly increasing the chances of desired pregnancy. Clinical trial registration number: NCT03422289 ( ClinicalTrials.gov registry).

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 75 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 13 17%
Researcher 9 12%
Student > Ph. D. Student 7 9%
Student > Bachelor 7 9%
Student > Doctoral Student 5 7%
Other 13 17%
Unknown 21 28%
Readers by discipline Count As %
Medicine and Dentistry 23 31%
Biochemistry, Genetics and Molecular Biology 9 12%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Agricultural and Biological Sciences 5 7%
Nursing and Health Professions 3 4%
Other 6 8%
Unknown 24 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2019.
All research outputs
#2,801,765
of 16,380,257 outputs
Outputs from Journal of Ovarian Research
#36
of 383 outputs
Outputs of similar age
#68,432
of 283,802 outputs
Outputs of similar age from Journal of Ovarian Research
#1
of 1 outputs
Altmetric has tracked 16,380,257 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 383 research outputs from this source. They receive a mean Attention Score of 2.8. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,802 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them